System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 40766085 DOI: 10.3389/fmicb.2025.1630226

Epidemiology risk factors and antifungal resistance patterns of Candida in cancer patients in Jiangxi China.

Front Microbiol 16:1630226

Authors: Hazrat Bilal, Xiaohui Li, Xunsong Wang, Muhammad Nadeem Khan, Muhammad Shafiq, Jiamei Yu, Hanman Qiu, Qiao-Li Lv, Bin Xu

Affiliations

  • Jiangxi Key Laboratory of Oncology (2024SSY06041), JXHC Key Laboratory of Tumor Metastasis, NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China.
  • Department of Medical Laboratory, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, Jiangxi, China.
  • Department of Cell Biology and Genetics, Shantou University Medical College, Shantou, China.
  • Department of Pharmacology, Research Institute of Clinical Pharmacy, Shantou University Medical College, Shantou, China.

Abstract

Background

Candidiasis in cancer patients remains largely unexplored in China. This study examines risk factors and antifungal susceptibility patterns of Candida in cancer patients from Jiangxi, China.

Methods

Clinical and demographic data on Candida in cancer patients (2018-2024) were retrospectively collected at Jiangxi Cancer Hospital, Nanchang, China. Candida distribution across cancers and antifungal susceptibility patterns were analyzed. Risk factors were identified via logistic regression, and antifungal consumption was correlated with Candida distribution. Survival probabilities were compared between patients with C. albicans and those with non-albicans Candida (NAC) infections.

Results

Among 2,761 Candida isolates, 1,703 (61.68%) were C. albicans and 1,058 (38.31%) were NAC, with a year-wise trend showing a decline in C. albicans and a rise in NAC. C. albicans was significantly higher in lung (40.57%) and nasopharyngeal (11.33%) cancers, while NAC were more common in gastric (7.56%), colon (8.69%), and urogenital (14.65%) cancers. NAC risk factors included inappropriate empirical therapy (OR 13.8, P < 0.001), hypoproteinemia (OR 1.35), anemia (OR 1.28), urinary tract infection (OR 1.71), and indwelling catheters (OR 1.27) (all P < 0.05). Radiotherapy, targeted therapy, glucocorticoids, chest tube insertion, and parenteral nutrition were associated with C. albicans (P ≤ 0.01). Amphotericin B (>99%) and echinocandins (>96%) showed the highest efficacy. C. tropicalis displayed notable azole resistance (40.9-74.45%). Caspofungin use negatively correlated with C. albicans (r = -0.84, P = 0.02) and positively with C. tropicalis (r = 0.78, P = 0.04) and N. glabrata (r = 0.85, p = 0.02). NAC infections showed 1.5-fold higher mortality rate than C. albicans (95% CI: 1.1-2.0; P = 0.0075).

Conclusion

These findings may aid healthcare officials in improving Candida management in the region and similar settings.

MeSH

Epidemiology, Neoplasms, Risk Factors, Amphotericin B, Therapeutics, Candida, Infections